Clinical ScienceSystemic Absorption of Mitomycin-C When Used in Pterygium SurgeryYulish, Michael MD*,†; Khatib, Ahmed MD‡; Pikkel, Joseph MD§Author Information *Ophthalmology Department, Ziv Medical Center, Safed, Israel; †Faculty of Medicine, Bar Ilan University, Ramat Gan, Israel; ‡Ophthalmology Department, Bnai Zion Medical Center, Haifa, Israel; and §Ophthalmology Department, Assuta Ashdod Hospital, Ashdod, Israel. Correspondence: Michael Yulish, MD, Ziv Medical Center, Safed, Israel 13100 (e-mail: [email protected]). The authors have no funding or conflicts of interest to disclose. Cornea: June 2018 - Volume 37 - Issue 6 - p 746-747 doi: 10.1097/ICO.0000000000001506 Buy Metrics Abstract Purpose: To determine whether scleral topical application of mitomycin-C (MMC) results in measurable plasma levels of systemic absorption. Methods: The study comprised 27 patients who were treated with MMC 0.2 mg/mL (0.02%) for 60 seconds during pterygium surgery. Blood samples were taken 30 minutes after surgery and evaluated by the human plasma liquid chromatography tandem-mass spectrometry method to determine the presence of MMC. Results: The amount of MMC in 27 samples tested was determined as below 0.25 ppb (ng/mL). Conclusions: In this study of 27 patients treated with topical application of MMC for pterygium surgery, there was no measurable evidence of systemic drug absorption. Although systemic absorption has been found with the use of larger quantities of MMC, there is an extremely low likelihood of systemic absorption or toxicity of MMC after pterygium surgery. Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.